ES2572915T3 - Nanopartículas conjugadas a un agente antinucleolina - Google Patents

Nanopartículas conjugadas a un agente antinucleolina Download PDF

Info

Publication number
ES2572915T3
ES2572915T3 ES12730288.3T ES12730288T ES2572915T3 ES 2572915 T3 ES2572915 T3 ES 2572915T3 ES 12730288 T ES12730288 T ES 12730288T ES 2572915 T3 ES2572915 T3 ES 2572915T3
Authority
ES
Spain
Prior art keywords
gro
human
antinucleolin
nucleolin
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12730288.3T
Other languages
English (en)
Inventor
Paula J. Bates
Mohammad Tariq MALIK
Kyung A. Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Application granted granted Critical
Publication of ES2572915T3 publication Critical patent/ES2572915T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composición, que comprende un agente antinucleolina conjugado a nanopartículas, en la que las nanopartículas no son magnéticas, ni de óxido de hierro, ni de poliacrilamida, y en la que las nanopartículas comprenden al menos un miembro seleccionado del grupo que consiste en oro, platino, iridio y paladio, y en la que el agente antinucleolina comprende: a) un oligonucleótido antinucleolina; y/o b) un anticuerpo; y/o c) una proteína de reconocimiento de nucleolina; y/o d) un GRO (oligonucléotido rico en guanosina).

Description

imagen1
imagen2
imagen3
Las Figuras 13A y B muestran la biodistribución de AS1411-GNP-Cy5: los ratones fueron tratados, sacrificados y se fotografiaron los órganos (A) y se examinaron para analizar la fluorescencia (B).
5 DESCRIPCIÓN DETALLADA
[0026] La presente invención hace uso del descubrimiento de que los agentes antinucleolina, conjugados a partículas, tales como aptámero conjugado a nanopartículas de oro, tienen un efecto antiproliferativo sobre el cáncer y tumores. Además, el aptámero conjugado a nanopartículas de oro en particular, tiene un efecto antiproliferativo 10 similar o mayor que el aptámero (oligonucleótido antinucleolina) por sí solo, demostrando efectos similares a solo de 1/10 a 1/100 de la dosis. Además, estos mismos agentes, que tienen preferiblemente un colorante fluorescente conjugado a la partícula o unida al agente antinucleolina, también se pueden usar tambbién como agentes de obtención de imágenes, tanto in vivo como ex vivo.
15 [0027] Los agentes antinucleolina incluyen (i) aptámeros, tales como GRO; (ii) anticuerpos antinucleolina; y (iii) proteínas que reconocen nucleolina. Ejemplos de aptámeros incluyen oligonucleótidos ricos en guanosina (GRO). Ejemplos de oligonucleótidos y ensayos adecuados se proporciona también en Miller et al. [7]. Las características de GRO incluyen:
(1) que tienen al menos 1 motivo GGT, 20 (2) que tienen preferiblemente 4-100 nucleótidos, aunque GRO que tienen muchos más nucleótidos son posibles,
(3) que tienen opcionalmente modificaciones químicas para mejorar la estabilidad.
[0028] Los GRO especialmente útiles forman estructuras de cuarteto de G, tal como se indica por un perfil de desnaturalización/renaturalización térmica reversible a 295 nm [6]. Los GRO preferidos también compiten con un 25 oligonucleótido de telómero para la unión a una proteína celular diana en un ensayo de desplazamiento por movilidad electroforética [6]. En algunos casos, la incorporación de los nucleótidos GRO en secuencias de ácidos nucleicos más grandes puede ser ventajosa; por ejemplo, para facilitar la unión de un ácido nucleico de GRO a un sustrato sin desnaturalizar el sitio de unión a nucleolina. Los ejemplos de oligonucleótidos se muestran en la Tabla 1; los oligonucleótidos preferidos incluyen las SEQ ID NOs: 1-7; 9-16; 19-30 y 31 de la Tabla 1. 30 Tabla 1. Gros no antisentido que se unen nucleolina y controles que no se unen1,2,3 .
GRO
Secuencia SEQ ID NO:
GRO29A1
tttggtggtg gtggttgtgg tggtggtgg 1
GRO29-2
tttggtggtg gtggttttgg tggtggtgg 2
GRO29-3
tttggtggtg gtggtggtgg tggtggtgg 3
GRO29-5
tttggtggtg gtggtttggg tggtggtgg 4
GRO29-13
tggtggtggt ggt 5
GRO14C
ggtggttgtg gtgg 6
GRO15A
gttgtttggg gtggt 7
GRO15B2
ttgggggggg tgggt 8
GRO25A
ggttggggtg ggtggggtgg gtggg 9
GRO26B1
ggtggtggtg gttgtggtgg tggtgg 10
GRO28A
tttggtggtg gtggttgtgg tggtggtg 11
GRO28B
tttggtggtg gtggtgtggt ggtggtgg 12
GRO29-6
ggtggtggtg gttgtggtgg tggtggttt 13
GRO32A
ggtggttgtg gtggttgtgg tggttgtggt gg 14
GRO32B
tttggtggtg gtggttgtgg tggtggtggt tt 15
GRO56A
ggtggtggtg gttgtggtgg tggtggttgt ggtggtggtg gttgtggtgg tggtgg 16
CRO
tttcctcctc ctccttctcc tcctcctcc 18
GRO A
ttagggttag ggttagggtt aggg 19
GRO B
ggtggtggtg g 20
GRO C
ggtggttgtg gtgg 21
GRO D
ggttggtgtg gttgg 22
GRO E
gggttttggg 23
GRO F
ttggttttgg ggttttggtt 24
GRO G1
ggttggtgtg gttgg 25
GRO H1
ggggttttgg 26
GRO I1
gggttttggg 27
GRO J1
ggggttttgg ggttttgggg ttttgggg 28
GRO K1
ttggggttgg ggttggggtt gggg 29
GRO L1
gggtgggtgg gtgggt 30
GRO M1
ttggttttgg ggttttggtt ttttgg 31
5
GRO N2
tttcctcctc ctccttctcc tcctcctcc 32
GRO O2
cctcctcctc cttctcctcc tcctcc 33
GRO P2
tggggt 34
GRO Q2
gcatgct 35
GRO R2
gcggtttgcg g 36
GRO S2
tagg 37
GRO T2
ggggttgggg tgtggggttg 38
1Indica un buen GRO que se une a nucleolina de membrana plasmática. 2Indica un control de nucleolina (unión a nucleolina no de membrana plasmática). 3Secuencias de GRO sin las denominaciones 1 o 2 tienen cierta actividad antiproliferativa.
[0029] También se puede usar cualquier anticuerpo que se une a nucleolina. En ciertos casos se prefieren anticuerpos monoclonales ya que se unen a epítopos individuales, específicos y definidos. En otros casos, sin embargo, se pueden usar anticuerpos policlonales capaces de interactuar con más de un epítopo en la nucleolina. Muchos anticuerpos antinucleolina están disponibles comercialmente, y de cualquier forma, se fabrican fácilmente. La Tabla 2 enumera unos cuantos anticuerpos antinucleolina disponibles comercialmente.
Tabla 2: Anticuerpos antinucleolina disponibles comercialmente
Anticuerpo
Fuente Fuente de antígeno
Anticuerpo monoclonal (mAb) de ratón p7-1A4
Developmental Studies Hybridoma Bank Oocitos de Xehopus laevis
mAb de ratón Sc-8031
Santa Cruz Biotech Humana
Ab policlonal (pAb) de cabra Sc-9893
Santa Cruz Biotech Humana
pAb de cabra Sc-9892
Santa Cruz Biotech Humana
mAb de ratón clon 4E2
MBL International Humana
mAb de ratón clon 3G4B2
Upstate Biotechnology Perro (células MDCK)
Nucleolina, humana (mAb de ratón)
MyBioSource Humana
Antinucleolina-Fosfo purificado, Thr76/Thr84 (mAb de ratón)
BioLegend Humana
Anticuerpo policlonal de Nucleolina de Conejo
Novus Biologicals Humana
Nucleolina (NCL, C23, FLJ45706)
US Biological Humana
FLJ59041, Proteína C23, mAb Mo xHu
Humana
Nucleolina (NCL, Nucl, C23, FLJ45706, Proteína C23) Pab Rb xHu
US Biological Humana
mAb antinucleolina humana Fosfo-Thr76/Thr84 de ratón, clon 10C7
Cell Sciences Humana
Anti-NCL / Nucleolina (pAb)
LifeSpan Biosciences Humana
Anticuerpo policlonal de ratón MaxPab purificado de NCL (B02P)
Abnova Humana
Anticuerpo policlonal de conejo MaxPab purificado de NCL (D01 P)
Abnova Humana
Anticuerpo monoclonal de NCL, clon 10C7 (mAb de ratón)
Abnova Humana
Anticuerpo monoclonal de nucleolina (4E2) (mAb de ratón)
Enzo Life Sciences Humana
Nucleolina, Anticuerpo Monoclonal de Ratón
Life Technologies Corporation Humana
Anticuerpo de NCL (Centro E443) (pAb de conejo)
Abgent Humana
Antinucleolina, clon 3G4B2 (mAb de ratón)
EMD Milipore Humana
NCL (pAb de conejo)
Proteintech Group Humana
Anticuerpo Monoclonal Antinucleolina de Ratón, sin conjugar, clon 3G4B20
Active Motif Humana
Nsr1p – monoclonal de ratón
EnCor Biotechnology Humana
Nucleolina (mAb de ratón)
Thermo Scientific Pierce Products Humana
Anticuerpo [4E2] de nucleolina (mAb de ratón)
GeneTex Humana
10 [0030] Las proteínas de reconocimiento de nucleolina son proteínas, diferentes de anticuerpos, que se unen específica y selectivamente a nucleolina. Los ejemplos incluyen la proteína ribosomal S3, péptidos F3 de migración tumoral [26, 27] y la miosina H9 (una miosina no muscular que se une la nucleolina de la superficie celular de las células endoteliales en vasos angiogénicos durante la tumorigénesis).
15 [0031] Los agentes antinucleolina se pueden conjugar a partículas fabricadas de una variedad de materiales, materiales sólidos, incluyendo (1) metales y elementos; (2) óxidos; (3) semiconductores; y (4) polímeros. Los
6
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10

Claims (1)

  1. imagen1
ES12730288.3T 2011-06-02 2012-06-01 Nanopartículas conjugadas a un agente antinucleolina Active ES2572915T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492683P 2011-06-02 2011-06-02
US201161492683P 2011-06-02
PCT/US2012/040577 WO2012167173A1 (en) 2011-06-02 2012-06-01 Anti-nucleolin agent-conjugated nanoparticles

Publications (1)

Publication Number Publication Date
ES2572915T3 true ES2572915T3 (es) 2016-06-03

Family

ID=46395687

Family Applications (3)

Application Number Title Priority Date Filing Date
ES15182208.7T Active ES2690557T3 (es) 2011-06-02 2012-06-01 Nanopartículas conjugadas a un agente antinucleolina
ES12730288.3T Active ES2572915T3 (es) 2011-06-02 2012-06-01 Nanopartículas conjugadas a un agente antinucleolina
ES18185333T Active ES2880291T3 (es) 2011-06-02 2012-06-01 Nanopartículas conjugadas a un agente antinucleolina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES15182208.7T Active ES2690557T3 (es) 2011-06-02 2012-06-01 Nanopartículas conjugadas a un agente antinucleolina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18185333T Active ES2880291T3 (es) 2011-06-02 2012-06-01 Nanopartículas conjugadas a un agente antinucleolina

Country Status (7)

Country Link
US (3) US9452219B2 (es)
EP (3) EP2714094B1 (es)
DK (2) DK3446714T3 (es)
ES (3) ES2690557T3 (es)
PL (1) PL3446714T3 (es)
PT (1) PT3446714T (es)
WO (1) WO2012167173A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EP2714094B1 (en) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
KR101596552B1 (ko) * 2013-02-13 2016-02-23 중앙대학교 산학협력단 금나노입자-앱타머 결합체를 기반으로 하는 단백질 전달체 및 이의 제조 방법
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
WO2017011411A1 (en) * 2015-07-10 2017-01-19 Ohio State Innovation Foundation Methods and compositions relating to anti-nucleolin recombinant immunoagents
JP7157981B2 (ja) * 2016-03-07 2022-10-21 チャールストンファーマ， エルエルシー 抗ヌクレオリン抗体
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
WO2019079164A1 (en) * 2017-10-16 2019-04-25 University Of Cincinnati COMBINATION OF AS1411 AND SAPC-DOPS FOR THE TREATMENT OF MULTIPLE GLIOBLASTOMA
EP4028062A2 (en) 2019-09-10 2022-07-20 University of Louisville Research Foundation, Inc. Anti-nucleolin agent-peg-conjugated nanoparticles
US20210299156A1 (en) * 2020-03-28 2021-09-30 Qualigen Inc. Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent
KR20210143127A (ko) 2020-05-19 2021-11-26 애니젠 주식회사 신규 뉴클레오린-결합 펩타이드 및 이의 용도
USD952157S1 (en) 2020-06-19 2022-05-17 Qualigen Inc. Whole blood treatment cartridge

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4474892A (en) 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4665897A (en) 1984-05-25 1987-05-19 Lemelson Jerome H Composition and method for detecting and treating cancer
US5055459A (en) 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192660A (en) 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
AU635008B2 (en) 1989-12-13 1993-03-11 Genelabs Diagnostics Pte Ltd Analytical apparatus and method for automated blot assay
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5736348A (en) 1990-11-28 1998-04-07 Fundacao Oswaldo Cruz (Fiocruz) Method for the immunological diagnosis of Chagas' Disease using recombinant antigens
JPH05244988A (ja) 1992-03-04 1993-09-24 Green Cross Corp:The 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
JPH07242566A (ja) 1994-03-01 1995-09-19 Kirin Brewery Co Ltd 免疫抑制剤
US5691447A (en) 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
US6096532A (en) 1995-06-07 2000-08-01 Aastrom Biosciences, Inc. Processor apparatus for use in a system for maintaining and growing biological cells
EP0883344B2 (en) 1995-12-15 2010-06-09 VIRxSYS Corporation Therapeutic molecules generated by trans-splicing
US6582921B2 (en) * 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
CA2284084A1 (en) 1997-03-12 1998-09-17 Institut Pasteur A novel cell surface receptor for hiv retroviruses, therapeutic and diagnostic uses
AU739350B2 (en) 1997-06-05 2001-10-11 University Of Texas System, The APAF-1, the CED-4 human homolog, an activator of caspase-3
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
WO1999006588A1 (en) 1997-08-04 1999-02-11 The Burnham Institute A cell-free system of mitochondria-dependent apoptosis, and methods of use thereof
US6325785B1 (en) 1997-08-14 2001-12-04 Sherwood Services Ag Sputum trap manifold with nested caps
US5925334A (en) 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US5932475A (en) 1997-12-12 1999-08-03 Incyte Pharmaceuticals, Inc. Human nucleolin-like protein
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU762572B2 (en) 1998-04-10 2003-06-26 Chugai Seiyaku Kabushiki Kaisha Protein and gene involved in myocyte differentiation
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
DE69937835T2 (de) 1998-09-24 2009-01-02 Promega Corp., Madison Antikörper für apoptosemarker und anwendungsverfahren
DK1181304T3 (da) * 1999-04-08 2008-02-11 Antisoma Res Ltd Antiproliferativ virkning af G-rige oligonucleotider samt fremgangsmåde til anvendelse af dem til binding af nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
EP1173486A1 (en) 1999-04-15 2002-01-23 Merck Frosst Canada & Co. Antibodies that recognize app cleaved by caspases and methods of use
US6165786A (en) 1999-11-03 2000-12-26 Isis Pharmaceuticals, Inc. Antisense modulation of nucleolin expression
EP1229328B1 (en) 1999-11-08 2007-06-20 Eisai Co., Ltd. Method of detecting cell death using cytochrome C.
JP2001213804A (ja) 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd 抗組織因子抗体の複合体
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
AT411326B (de) 2000-06-20 2003-12-29 Biering Wolfgang Hämostatische collagen-pellets
DE10037861A1 (de) 2000-08-01 2002-02-14 Max Delbrueck Centrum Mittel zur Therapie maligner Erkrankungen
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AR036169A1 (es) 2001-07-16 2004-08-18 Arla Foods Amba Procedimiento para la elaboracion de tagatosa
AU2002362436A1 (en) 2001-10-03 2003-04-14 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
WO2003087124A2 (en) 2002-04-05 2003-10-23 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
JP2005530515A (ja) 2002-06-26 2005-10-13 ユニヴァーシティー オヴ ルイスヴィル リサーチ ファウンデイション インコーポレイテッド アポトーシスの検出方法
US20070128117A1 (en) 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
TW200504210A (en) 2003-07-30 2005-02-01 Chin-Tarng Lin A nucleolin antisense inhibiting growth of cancer cell
WO2005037323A2 (en) 2003-10-10 2005-04-28 University Of Louisville Research Foundation, Inc. Use of gro to treat or prevent inflammation
NZ546557A (en) 2003-10-17 2010-01-29 Chugai Pharmaceutical Co Ltd Therapeutic agent for mesothelioma comprising interleukin-6
PL1687066T3 (pl) 2003-11-14 2013-01-31 Brigham & Womens Hospital Inc Sposoby modulowania odporności
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
CN1862258B (zh) 2005-05-12 2012-05-30 清华大学 核仁素辅助的癌症诊断与治疗方法
WO2007016466A2 (en) * 2005-07-29 2007-02-08 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses therefor
WO2009088837A2 (en) 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
AU2010202113A1 (en) 2009-05-25 2010-12-09 Markelee Pty Ltd Pipe lifting device
EP2440186B1 (en) 2009-06-12 2019-08-07 MannKind Corporation Diketopiperazine microparticles with defined isomer contents
WO2011050177A1 (en) 2009-10-21 2011-04-28 Health Research, Inc. Paa nanoparticles for enhancement of tumor imaging
US20110111002A1 (en) * 2009-11-12 2011-05-12 Calin Viorel Pop Transport and delivery of glutathione into human cells using gold nanoparticles
WO2011062997A2 (en) * 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
US8589851B2 (en) 2009-12-15 2013-11-19 Memoir Systems, Inc. Intelligent memory system compiler
JP5391049B2 (ja) 2009-12-21 2014-01-15 パナホーム株式会社 外壁パネルの施工方法
WO2011119058A2 (en) 2010-03-22 2011-09-29 Universidade De Coimbra F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases
US20120107242A1 (en) * 2010-09-30 2012-05-03 The Board Of Trustees Of The University Of Illinois Nucleic acid-mediated shape control of nanoparticles for biomedical applications
EP2497828A1 (en) 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
EP2714094B1 (en) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
US9642805B2 (en) 2011-11-07 2017-05-09 Northwestern University Aptamer-loaded, biocompatible nanoconstructs for nuclear-targeted cancer therapy
EP2982756A1 (en) 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
WO2018026958A1 (en) 2016-08-02 2018-02-08 The University Of Louisville Research Foundation, Inc. Targeted nanodroplet emulsions for treating cancer
CN117653654A (zh) 2016-11-23 2024-03-08 柏林制药股份有限公司 用于抑制和/或压制tlr9激活的适体
EP4028062A2 (en) 2019-09-10 2022-07-20 University of Louisville Research Foundation, Inc. Anti-nucleolin agent-peg-conjugated nanoparticles
US20210299156A1 (en) 2020-03-28 2021-09-30 Qualigen Inc. Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent

Also Published As

Publication number Publication date
ES2880291T3 (es) 2021-11-24
US11344633B2 (en) 2022-05-31
DK3011974T3 (en) 2018-11-12
EP2714094B1 (en) 2016-02-24
WO2012167173A1 (en) 2012-12-06
PT3446714T (pt) 2021-06-23
US20140170076A1 (en) 2014-06-19
EP3011974A1 (en) 2016-04-27
US20170095562A1 (en) 2017-04-06
US9452219B2 (en) 2016-09-27
US20220265867A1 (en) 2022-08-25
EP3011974B1 (en) 2018-08-08
EP3446714B1 (en) 2021-03-31
EP2714094A1 (en) 2014-04-09
EP3446714A1 (en) 2019-02-27
ES2690557T3 (es) 2018-11-21
DK3446714T3 (da) 2021-05-10
PL3446714T3 (pl) 2021-11-22

Similar Documents

Publication Publication Date Title
ES2572915T3 (es) Nanopartículas conjugadas a un agente antinucleolina
Yan et al. Advances in aptamer screening technologies
Kim et al. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells
ES2531515T3 (es) Método para modificar receptores de células T
ES2539593T3 (es) Inmunoglobulinas multivalentes modificadas en la región de bucle estructural
Gijs et al. Aptamers as radiopharmaceuticals for nuclear imaging and therapy
Wang et al. Microarray based screening of peptide nano probes for HER2 positive tumor
ES2369383T3 (es) Método auxiliar para diagnosis y terapia de cáncer con nucleolina.
Kim et al. PET imaging of HER2 expression with an 18F-fluoride labeled aptamer
CN107207574A (zh) 血管生成特异性的新型蛋白
JP2012520059A (ja) プロタンパク質およびその使用方法
Filippi et al. Aptamer-based technology for radionuclide targeted imaging and therapy: A promising weapon against cancer
Pereira et al. Aptamers: Novelty tools for cancer biology
Perkins et al. Radiolabelled aptamers for tumour imaging and therapy
Zhang et al. A cell-based single-stranded DNA aptamer specifically targets gastric cancer
Arcangeli et al. The Junctional Adhesion Molecule-B regulates JAM-C-dependent melanoma cell metastasis
Barman Targeting cancer cells using aptamers: Cell-SELEX approach and recent advancements
Cho et al. Viral nanoparticles decorated with novel EGFL7 ligands enable intravital imaging of tumor neovasculature
JP2011504361A5 (es)
US20230127087A1 (en) Glypican-3-specific modified aptamer and use thereof
JP2023532032A (ja) 血液脳関門浸透アプタマー及びその利用
KR102065112B1 (ko) 높은 항원 선택성을 갖는 항체의 스크리닝 방법
Vorhies et al. Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics
Yang et al. A novel His-tag-binding aptamer for recombinant protein detection and T cell-based immunotherapy
Coker-Gurkan et al. Applications of aptamers in cancer therapy